Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Consensus Statement of the European Group on Graves’ Orbitopathy (EUGOGO) on Management of Graves’ Orbitopathy
source: Thyroid : Official Journal of the American Thyroid Association
year: 2008
authors: Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM
summary/abstract:Graves’ orbitopathy (GO) constitutes a major clinical and therapeutic challenge. GO is an autoimmune disorder representing the commonest and most important extrathyroidal manifestation of Graves’ disease, but it may occur in patients without current or prior hyperthyroidism (euthyroid or ophthalmic Graves’ disease) or in patients who are hypothyroid due to chronic autoimmune (Hashimoto’s) thyroiditis. Although the pathogenesis of GO (5–9) is beyond the scope of this document, attention is drawn to the link between the orbit and thyroid, which has important clinical and therapeutic implications. Optimal management of GO requires a coordinated approach addressing the thyroid dysfunction and the orbitopathy.
GO is often mild and self-limiting, and probably declining in frequency, with only 3–5% of cases posing a threat to eyesight. The onset and progression of GO are influenced by factors that are potentially controllable such as cigarette smoking, thyroid dysfunction, and choice of treatment modalities for hyperthyroidism.
organization: University of Insubria, Varese, Italy; Catholic University of Louvain, Belgium; Aristotle University of Thessaloniki, Greece, Universitätsklinikum Essen, Germany; Johannes Gutenberg University (JGU) Medical Center, Germany; University of Pisa, Italy; Newcastle upon Tyne Hospitals NHS Foundation Trust, UK; University of Milan, Italy; University of Amsterdam, NetherlandsDOI: 10.1089/thy.2007.0315
read more full text
myBinderRelated Content
-
Focusing on TED: Rare but devastatingThyroid eye disease (TED) is a rare auto...
-
Pathogenesis of Thyroid Eye Disease: Review and Update on Molecular MechanismsOrbital changes in thyroid orbitopathy (...
-
Patient Story – Thyroid Eye Diseasehttps://www.youtube.com/watch?v=GnXbXSah...
-
Charles Sydnor, MDCharles Sydnor began his private ophthal...
-
Meeting of Dermatologic and Ophthalmic Drugs Advisory Committee AnnouncementThe committee will discuss biologics lic...
-
Quality of Life, Clinical Outcomes and Safety of Early Prophylactic Levothyroxine Administration in Patients With Gr...Objective: While radioiodine therapy is...
-
The Thyroid Diet: Is There Such a Thing?Thyroid disease includes hypothyroidism,...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google